Novelty Nobility announced on the 11th that it has appointed Dr. Park Chan-hee as its new Chief Scientific Officer (CSO) and Senior Vice President.
With this appointment, CEO Park Sang-kyu, who previously held concurrent roles as CSO, will shift his position to CEO and Chief Technology Officer (CTO) to focus on antibody research.
Senior Vice President Park is a drug development expert who served in core research and development roles at JW Joong-wae Group for 30 years. After earning bachelor's and master's degrees in chemistry from Sungkyunkwan University, he obtained his doctorate from Seoul National University's College of Pharmacy. He joined LG Chem Research Institute in 1995 before moving to JW Joong-wae Group in 1996.
During his tenure at JW, he served as Group CTO and head of JW C&C's New Drug Research Institute, overseeing innovative drug programs from early target discovery through clinical stages.
Park demonstrated commercial success by licensing proprietary drug programs to Japan's Chugai, China's Simcere, and Denmark's LEO Pharma. He also led platform-based partnerships and early-stage investments by identifying promising biotechs with domestic and international venture capital firms. He forged strategic partnerships with universities, hospitals, and research institutions across North America, Europe, and Asia-Pacific to pursue joint R&D initiatives.
Park contributed to building innovative drug development infrastructure by spearheading the establishment of AI-based drug R&D platforms and automated laboratories.
"Following our recruitment of a Chief Medical Officer specializing in global clinical development, this CSO appointment completes our full-cycle R&D leadership spanning early research to clinical development," said CEO Park Sang-kyu. "We will accelerate our R&D capabilities and global commercialization based on Senior Vice President Park's expertise and leadership."
"I will contribute to developing world-class innovative drugs in the immunology and inflammatory disease fields by combining my drug development know-how with Novelty Nobility's unparalleled antibody technology," said Senior Vice President Park.
